39.84 USD
+0.3 (+0.76%)
39.96 USD
+0.12 (+0.3%)
RPRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. RPRX has an excellent profitability rating, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on RPRX.
1. Profitability
1.1 Basic Checks
In the past year RPRX was profitable.
In the past year RPRX had a positive cash flow from operations.
Each year in the past 5 years RPRX has been profitable.
In the past 5 years RPRX always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.95%, RPRX belongs to the top of the industry, outperforming 84.90% of the companies in the same industry.
RPRX has a Return On Equity of 11.93%. This is amongst the best in the industry. RPRX outperforms 86.98% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.43%, RPRX belongs to the top of the industry, outperforming 84.38% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for RPRX is significantly below the industry average of 12.71%.
The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROIC | 6.43% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
The Profit Margin of RPRX (32.55%) is better than 95.83% of its industry peers.
RPRX's Profit Margin has declined in the last couple of years.
RPRX has a better Operating Margin (65.22%) than 100.00% of its industry peers.
In the last couple of years the Operating Margin of RPRX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RPRX is destroying value.
RPRX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for RPRX has been increased compared to 5 years ago.
RPRX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.71, we must say that RPRX is in the distress zone and has some risk of bankruptcy.
RPRX's Altman-Z score of 1.71 is in line compared to the rest of the industry. RPRX outperforms 59.38% of its industry peers.
RPRX has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as RPRX would need 9.47 years to pay back of all of its debts.
RPRX's Debt to FCF ratio of 9.47 is fine compared to the rest of the industry. RPRX outperforms 78.13% of its industry peers.
RPRX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
RPRX has a Debt to Equity ratio of 1.34. This is in the lower half of the industry: RPRX underperforms 76.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 1.71 |
ROIC/WACC0.79
WACC8.13%
2.3 Liquidity
RPRX has a Current Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
RPRX has a Current ratio (3.48) which is in line with its industry peers.
A Quick Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.48, RPRX is in line with its industry, outperforming 56.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
RPRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.24%.
RPRX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -18.23% yearly.
The Revenue has been growing slightly by 3.70% in the past year.
RPRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.52% yearly.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
The Earnings Per Share is expected to grow by 12.58% on average over the next years. This is quite good.
RPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.36% yearly.
EPS Next Y11.77%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
EPS Next 5Y12.58%
Revenue Next Year14.96%
Revenue Next 2Y8.31%
Revenue Next 3Y7.87%
Revenue Next 5Y10.36%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 9.69 indicates a reasonable valuation of RPRX.
Based on the Price/Earnings ratio, RPRX is valued cheaper than 91.15% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.15, RPRX is valued rather cheaply.
A Price/Forward Earnings ratio of 7.86 indicates a rather cheap valuation of RPRX.
Based on the Price/Forward Earnings ratio, RPRX is valued cheaper than 91.15% of the companies in the same industry.
RPRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.12, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.69 | ||
| Fwd PE | 7.86 |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 82.29% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.59 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RPRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y11.15%
EPS Next 3Y11.71%
5. Dividend
5.1 Amount
RPRX has a Yearly Dividend Yield of 2.29%. Purely for dividend investing, there may be better candidates out there.
RPRX's Dividend Yield is rather good when compared to the industry average which is at 7.92. RPRX pays more dividend than 93.23% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, RPRX has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.29% |
5.2 History
RPRX has been paying a dividend for over 5 years, so it has already some track record.
RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
49.36% of the earnings are spent on dividend by RPRX. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
39.84
+0.3 (+0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.15%
Inst Owner Change-2.77%
Ins Owners1.79%
Ins Owner Change9.31%
Market Cap23.23B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts82.67
Price Target46 (15.46%)
Short Float %3.61%
Short Ratio3.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.29% |
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)3.8%
PT rev (3m)4.2%
EPS NQ rev (1m)2.64%
EPS NQ rev (3m)7.2%
EPS NY rev (1m)0.13%
EPS NY rev (3m)-0.2%
Revenue NQ rev (1m)4.57%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)1.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.69 | ||
| Fwd PE | 7.86 | ||
| P/S | 9.89 | ||
| P/FCF | 24.59 | ||
| P/OCF | 9.66 | ||
| P/B | 3.62 | ||
| P/tB | 4.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.11
EY10.32%
EPS(NY)5.07
Fwd EY12.71%
FCF(TTM)1.62
FCFY4.07%
OCF(TTM)4.12
OCFY10.35%
SpS4.03
BVpS11
TBVpS9.41
PEG (NY)0.82
PEG (5Y)N/A
Graham Number31.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROCE | 8.15% | ||
| ROIC | 6.43% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 7.53% | ||
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A | ||
| FCFM | 40.2% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 62.15% | ||
| Interest Coverage | -5.67 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 123.5% | ||
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 1.71 |
F-Score5
WACC8.13%
ROIC/WACC0.79
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y11.77%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
EPS Next 5Y12.58%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year14.96%
Revenue Next 2Y8.31%
Revenue Next 3Y7.87%
Revenue Next 5Y10.36%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year28.89%
EBIT Next 3Y14.6%
EBIT Next 5Y13.36%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status of ROYALTY PHARMA PLC- CL A (RPRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
Can you provide the profitability details for ROYALTY PHARMA PLC- CL A?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 9.69 and the Price/Book (PB) ratio is 3.62.
Is the dividend of ROYALTY PHARMA PLC- CL A sustainable?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.36%.